Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Molecular Pain
Published in: Molecular Pain 1/2009

Open Access 01-12-2009 | Research

Lysophosphatidic acid-3 receptor-mediated feed-forward production of lysophosphatidic acid: an initiator of nerve injury-induced neuropathic pain

Authors: Lin Ma, Hitoshi Uchida, Jun Nagai, Makoto Inoue, Jerold Chun, Junken Aoki, Hiroshi Ueda

Published in: Molecular Pain | Issue 1/2009

Login to get access

Abstract

Background

We previously reported that intrathecal injection of lysophosphatidylcholine (LPC) induced neuropathic pain through activation of the lysophosphatidic acid (LPA)-1 receptor, possibly via conversion to LPA by autotaxin (ATX).

Results

We examined in vivo LPA-induced LPA production using a biological titration assay with B103 cells expressing LPA1 receptors. Intrathecal administration of LPC caused time-related production of LPA in the spinal dorsal horn and dorsal roots, but not in the dorsal root ganglion, spinal nerve or sciatic nerve. LPC-induced LPA production was markedly diminished in ATX heterozygotes, and was abolished in mice that were deficient in LPA3, but not LPA1 or LPA2 receptors. Similar time-related and LPA3 receptor-mediated production of LPA was observed following intrathecal administration of LPA. In an in vitro study using spinal cord slices, LPA-induced LPA production was also mediated by ATX and the LPA3 receptor. Intrathecal administration of LPA, in contrast, induced neuropathic pain, which was abolished in mice deficient in LPA1 or LPA3 receptors.

Conclusion

These findings suggest that feed-forward LPA production is involved in LPA-induced neuropathic pain.
Appendix
Available only for authorised users
Literature
1.
Ojala PJ, Hirvonen TE, Hermansson M, Somerharju P, Parkkinen J: Acyl chain-dependent effect of lysophosphatidylcholine on human neutrophils. J Leukoc Biol 2007,82(6):1501–1509. 10.1189/jlb.0507292PubMedCrossRef
2.
Kishimoto T, Soda Y, Matsuyama Y, Mizuno K: An enzymatic assay for lysophosphatidylcholine concentration in human serum and plasma. Clin Biochem 2002,35(5):411–416. 10.1016/S0009-9120(02)00327-2PubMedCrossRef
3.
Yokota T, Hansson GK: Immunological mechanisms in atherosclerosis. J Intern Med 1995,238(6):479–489. 10.1111/j.1365-2796.1995.tb01229.xPubMedCrossRef
4.
Murugesan G, Fox PL: Role of lysophosphatidylcholine in the inhibition of endothelial cell motility by oxidized low density lipoprotein. J Clin Invest 1996,97(12):2736–2744. 10.1172/JCI118728PubMedCentralPubMedCrossRef
5.
Chisolm GM, Chai Y: Regulation of cell growth by oxidized LDL. Free Radic Biol Med 2000,28(12):1697–1707. 10.1016/S0891-5849(00)00227-6PubMedCrossRef
6.
Xu Y: Sphingosylphosphorylcholine and lysophosphatidylcholine: G protein-coupled receptors and receptor-mediated signal transduction. Biochim Biophys Acta 2002,1582(1–3):81–88.PubMedCrossRef
7.
Meyer zu Heringdorf D, Jakobs KH: Lysophospholipid receptors: signalling, pharmacology and regulation by lysophospholipid metabolism. Biochim Biophys Acta 2007,1768(4):923–940. 10.1016/j.bbamem.2006.09.026PubMedCrossRef
8.
Matsumoto T, Kobayashi T, Kamata K: Role of lysophosphatidylcholine (LPC) in atherosclerosis. Curr Med Chem 2007,14(30):3209–3220. 10.2174/092986707782793899PubMedCrossRef
9.
Kougias P, Chai H, Lin PH, Lumsden AB, Yao Q, Chen C: Lysophosphatidylcholine and secretory phospholipase A2 in vascular disease: mediators of endothelial dysfunction and atherosclerosis. Med Sci Monit 2006,12(1):RA5–16.PubMed
10.
Hall SM: The response of the (myelinating) Schwann cell population to multiple episodes of demyelination. J Neurocytol 1983,12(1):1–12. 10.1007/BF01148084PubMedCrossRef
11.
Ghasemlou N, Jeong SY, Lacroix S, David S: T cells contribute to lysophosphatidylcholine-induced macrophage activation and demyelination in the CNS. Glia 2007,55(3):294–302. 10.1002/glia.20449PubMedCrossRef
12.
Jeffery ND, Blakemore WF: Remyelination of mouse spinal cord axons demyelinated by local injection of lysolecithin. J Neurocytol 1995,24(10):775–781. 10.1007/BF01191213PubMedCrossRef
13.
Kotter MR, Zhao C, van Rooijen N, Franklin RJ: Macrophage-depletion induced impairment of experimental CNS remyelination is associated with a reduced oligodendrocyte progenitor cell response and altered growth factor expression. Neurobiol Dis 2005,18(1):166–175. 10.1016/j.nbd.2004.09.019PubMedCrossRef
14.
Ousman SS, David S: MIP-1alpha, MCP-1, GM-CSF, and TNF-alpha control the immune cell response that mediates rapid phagocytosis of myelin from the adult mouse spinal cord. J Neurosci 2001,21(13):4649–4656.PubMed
15.
Harrison B: Schwann cell and oligodendrocyte remyelination in lysolecithin-induced lesions in irradiated rat spinal cord. J Neurol Sci 1985,67(2):143–159. 10.1016/0022-510X(85)90111-XPubMedCrossRef
16.
Wallace VC, Cottrell DF, Brophy PJ, Fleetwood-Walker SM: Focal lysolecithin-induced demyelination of peripheral afferents results in neuropathic pain behavior that is attenuated by cannabinoids. J Neurosci 2003,23(8):3221–3233.PubMed
17.
Inoue M, Rashid MH, Fujita R, Contos JJ, Chun J, Ueda H: Initiation of neuropathic pain requires lysophosphatidic acid receptor signaling. Nat Med 2004,10(7):712–718. 10.1038/nm1060PubMedCrossRef
18.
Ueda H: Molecular mechanisms of neuropathic pain-phenotypic switch and initiation mechanisms. Pharmacol Ther 2006,109(1–2):57–77. 10.1016/j.pharmthera.2005.06.003PubMedCrossRef
19.
Ueda H: Peripheral mechanisms of neuropathic pain - involvement of lysophosphatidic acid receptor-mediated demyelination. Mol Pain 2008, 4: 11. 10.1186/1744-8069-4-11PubMedCentralPubMedCrossRef
20.
Inoue M, Ma L, Aoki J, Chun J, Ueda H: Autotaxin, a synthetic enzyme of lysophosphatidic acid (LPA), mediates the induction of nerve-injured neuropathic pain. Mol Pain 2008, 4: 6. 10.1186/1744-8069-4-6PubMedCentralPubMedCrossRef
21.
Inoue M, Xie W, Matsushita Y, Chun J, Aoki J, Ueda H: Lysophosphatidylcholine induces neuropathic pain through an action of autotaxin to generate lysophosphatidic acid. Neuroscience 2008,152(2):296–298. 10.1016/j.neuroscience.2007.12.041PubMedCrossRef
22.
Inoue M, Ma L, Aoki J, Ueda H: Simultaneous stimulation of spinal NK1 and NMDA receptors produces LPC which undergoes ATX-mediated conversion to LPA, an initiator of neuropathic pain. J Neurochem 2008, 107: 1556–1565. 10.1111/j.1471-4159.2008.05725.xPubMedCrossRef
23.
Tanaka M, Okudaira S, Kishi Y, Ohkawa R, Iseki S, Ota M, Noji S, Yatomi Y, Aoki J, Arai H: Autotaxin stabilizes blood vessels and is required for embryonic vasculature by producing lysophosphatidic acid. J Biol Chem 2006,281(35):25822–25830. 10.1074/jbc.M605142200PubMedCrossRef
24.
Contos JJ, Fukushima N, Weiner JA, Kaushal D, Chun J: Requirement for the lpA1 lysophosphatidic acid receptor gene in normal suckling behavior. Proc Natl Acad Sci USA 2000,97(24):13384–13389. 10.1073/pnas.97.24.13384PubMedCentralPubMedCrossRef
25.
Contos JJ, Ishii I, Fukushima N, Kingsbury MA, Ye X, Kawamura S, Brown JH, Chun J: Characterization of lpa(2) (Edg4) and lpa(1)/lpa(2) (Edg2/Edg4) lysophosphatidic acid receptor knockout mice: signaling deficits without obvious phenotypic abnormality attributable to lpa(2). Mol Cell Biol 2002,22(19):6921–6929. 10.1128/MCB.22.19.6921-6929.2002PubMedCentralPubMedCrossRef
26.
Contos JJ, Chun J: The mouse lp(A3)/Edg7 lysophosphatidic acid receptor gene: genomic structure, chromosomal localization, and expression pattern. Gene 2001,267(2):243–253. 10.1016/S0378-1119(01)00410-3PubMedCrossRef
27.
Umezu-Goto M, Kishi Y, Taira A, Hama K, Dohmae N, Takio K, Yamori T, Mills GB, Inoue K, Aoki J, et al.: Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J Cell Biol 2002,158(2):227–233. 10.1083/jcb.200204026PubMedCentralPubMedCrossRef
28.
Ishii I, Contos JJ, Fukushima N, Chun J: Functional comparisons of the lysophosphatidic acid receptors, LP(A1)/VZG-1/EDG-2, LP(A2)/EDG-4, and LP(A3)/EDG-7 in neuronal cell lines using a retrovirus expression system. Mol Pharmacol 2000,58(5):895–902.PubMed
29.
Hargreaves K, Dubner R, Brown F, Flores C, Joris J: A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 1988,32(1):77–88. 10.1016/0304-3959(88)90026-7PubMedCrossRef
30.
Rashid MH, Inoue M, Kondo S, Kawashima T, Bakoshi S, Ueda H: Novel expression of vanilloid receptor 1 on capsaicin-insensitive fibers accounts for the analgesic effect of capsaicin cream in neuropathic pain. J Pharmacol Exp Ther 2003,304(3):940–948. 10.1124/jpet.102.046250PubMedCrossRef
31.
Fujita R, Ma Y, Ueda H: Lysophosphatidic acid-induced membrane ruffling and brain-derived neurotrophic factor gene expression are mediated by ATP release in primary microglia. J Neurochem 2008,107(1):152–160. 10.1111/j.1471-4159.2008.05599.xPubMedCrossRef
32.
Sato K, Malchinkhuu E, Muraki T, Ishikawa K, Hayashi K, Tosaka M, Mochiduki A, Inoue K, Tomura H, Mogi C, et al.: Identification of autotaxin as a neurite retraction-inducing factor of PC12 cells in cerebrospinal fluid and its possible sources. J Neurochem 2005,92(4):904–914. 10.1111/j.1471-4159.2004.02933.xPubMedCrossRef
33.
van Meeteren LA, Moolenaar WH: Regulation and biological activities of the autotaxin-LPA axis. Prog Lipid Res 2007,46(2):145–160. 10.1016/j.plipres.2007.02.001PubMedCrossRef
34.
Aoki J, Inoue A, Okudaira S: Two pathways for lysophosphatidic acid production. Biochim Biophys Acta 2008,1781(9):513–518.PubMedCrossRef
35.
Aoki J: Mechanisms of lysophosphatidic acid production. Semin Cell Dev Biol 2004,15(5):477–489. 10.1016/j.semcdb.2004.05.001PubMedCrossRef
36.
Xie Y, Meier KE: Lysophospholipase D and its role in LPA production. Cell Signal 2004,16(9):975–981.PubMedCrossRef
37.
Kishimoto T, Matsuoka T, Imamura S, Mizuno K: A novel colorimetric assay for the determination of lysophosphatidic acid in plasma using an enzymatic cycling method. Clin Chim Acta 2003,333(1):59–67. 10.1016/S0009-8981(03)00165-7PubMedCrossRef
38.
Sugiura T, Nakane S, Kishimoto S, Waku K, Yoshioka Y, Tokumura A, Hanahan DJ: Occurrence of lysophosphatidic acid and its alkyl ether-linked analog in rat brain and comparison of their biological activities toward cultured neural cells. Biochim Biophys Acta 1999,1440(2–3):194–204.PubMedCrossRef
39.
Liliom K, Guan Z, Tseng JL, Desiderio DM, Tigyi G, Watsky MA: Growth factor-like phospholipids generated after corneal injury. Am J Physiol 1998,274(4 Pt 1):C1065–1074.PubMed
40.
van Meeteren LA, Ruurs P, Christodoulou E, Goding JW, Takakusa H, Kikuchi K, Perrakis A, Nagano T, Moolenaar WH: Inhibition of autotaxin by lysophosphatidic acid and sphingosine 1-phosphate. J Biol Chem 2005,280(22):21155–21161. 10.1074/jbc.M413183200PubMedCrossRef
41.
Eder AM, Sasagawa T, Mao M, Aoki J, Mills GB: Constitutive and lysophosphatidic acid (LPA)-induced LPA production: role of phospholipase D and phospholipase A2. Clin Cancer Res 2000,6(6):2482–2491.PubMed
42.
Fang X, Gaudette D, Furui T, Mao M, Estrella V, Eder A, Pustilnik T, Sasagawa T, Lapushin R, Yu S, et al.: Lysophospholipid growth factors in the initiation, progression, metastases, and management of ovarian cancer. Ann N Y Acad Sci 2000, 905: 188–208.PubMedCrossRef
43.
Goetzl EJ, Dolezalova H, Kong Y, Hu YL, Jaffe RB, Kalli KR, Conover CA: Distinctive expression and functions of the type 4 endothelial differentiation gene-encoded G protein-coupled receptor for lysophosphatidic acid in ovarian cancer. Cancer Res 1999,59(20):5370–5375.PubMed
44.
de Sampaio ESTC, Choi JW, Gardell SE, Herr DR, Rehen SK, Gomes FC, Chun J: Lysophosphatidic acid receptor-dependent secondary effects via astrocytes promote neuronal differentiation. J Biol Chem 2008,283(12):7470–7479. 10.1074/jbc.M707758200CrossRef
45.
Moller T, Contos JJ, Musante DB, Chun J, Ransom BR: Expression and function of lysophosphatidic acid receptors in cultured rodent microglial cells. J Biol Chem 2001,276(28):25946–25952. 10.1074/jbc.M102691200PubMedCrossRef
46.
Sorensen SD, Nicole O, Peavy RD, Montoya LM, Lee CJ, Murphy TJ, Traynelis SF, Hepler JR: Common signaling pathways link activation of murine PAR-1, LPA, and S1P receptors to proliferation of astrocytes. Mol Pharmacol 2003,64(5):1199–1209. 10.1124/mol.64.5.1199PubMedCrossRef
47.
Fujita R, Kiguchi N, Ueda H: LPA-mediated demyelination in ex vivo culture of dorsal root. Neurochem Int 2007,50(2):351–355. 10.1016/j.neuint.2006.09.003PubMedCrossRef
48.
Xie W, Matsumoto M, Chun J, Ueda H: Involvement of LPA1 receptor signaling in the reorganization of spinal input through Abeta-fibers in mice with partial sciatic nerve injury. Mol Pain 2008, 4: 46. 10.1186/1744-8069-4-46PubMedCentralPubMedCrossRef
49.
Ma L, Matsumoto M, Xie W, Inoue M, Ueda H: Evidence for lysophosphatidic acid 1 receptor signaling in the early phase of neuropathic pain mechanisms in experiments using Ki-1 a lysophosphatidic acid 1 receptor antagonist. J Neurochem 6425,109(2):603–610. 10.1111/j.1471-4159.2009.05987.xCrossRef
Metadata
Title
Lysophosphatidic acid-3 receptor-mediated feed-forward production of lysophosphatidic acid: an initiator of nerve injury-induced neuropathic pain
Authors
Lin Ma
Hitoshi Uchida
Jun Nagai
Makoto Inoue
Jerold Chun
Junken Aoki
Hiroshi Ueda
Publication date
01-12-2009
Publisher
BioMed Central
Published in
Molecular Pain / Issue 1/2009
Electronic ISSN: 1744-8069
DOI
https://doi.org/10.1186/1744-8069-5-64

Other articles of this Issue 1/2009

Molecular Pain 1/2009 Go to the issue

Research

Excitatory neurotransmitters in brain regions in interictal migraine patients

Research

Peripheral nerve injury sensitizes neonatal dorsal horn neurons to tumor necrosis factor-α

Short report

Do genetic predictors of pain sensitivity associate with persistent widespread pain?

Research

Upregulation of casein kinase 1ε in dorsal root ganglia and spinal cord after mouse spinal nerve injury contributes to neuropathic pain

Research

Antinociceptive action of oxytocin involves inhibition of potassium channel currents in lamina II neurons of the rat spinal cord

Research

Genetic variation in the serotonin transporter gene (5-HTTLPR, rs25531) influences the analgesic response to the short acting opioid Remifentanil in humans